Aeroscena®, LLC, Joins Children's National Health System for Aromatherapy-Based Pediatric Pain Study
Cleveland, Ohio (PRWEB) March 09, 2016 -- Children's National Health System is the site of a new research study, "A Feasibility Study of the Effects of Aromatherapy on the Incidence and Severity of Acute Pain in Pediatric Patients." The study will be conducted by Katherine Curtin, Principal Investigator, with the help of her research team: Dr. Pamela Hinds, Marian McEvilly, RN, Dr. Nora Stinley, Dr. Yunfei Wang, and Dr. Deborah Norris. The research is being supported by a generous donation from Aeroscena®.
"Aeroscena® is delighted to support Children's National Health System as they investigate the effects of aromatherapy in clinical settings," said Mark Kohoot, Founder and CEO of the company. "It is through scientific, data-driven collaborations like these that we hope to continue to demonstrate to the medical community its significant benefits." Located in the Cleveland Clinic GCIC, Aeroscena® is the world's leading resource for clinical aromatherapy. With a focus on developing scientifically-backed formulas and cutting-edge diffusion systems, Aeroscena® creates opportunities for better health safely and effectively in medical, commercial and consumer environments.
The purpose of this research is to estimate the feasibility of a non-pharmacological pain management intervention to reduce pain and distress caused by venipunctures in a pediatric population. The feasibility of the use of aromatherapy essential oil lavandula angustifolia for pain management intervention will be compared to placebo aromatherapy with jojoba oil and to the current standard of care, which is no oil during a venipuncture. Primary and secondary measured outcomes, including both physiological and psychological effects, will be assessed using a double-blind randomized design.
The research team is investigating the pattern of change that occurs during anticipatory anxiety resulting from the impending procedure, the procedural pain experienced during the venipuncture, and the residual fear common after completion. Participants are ages 7 to 11 years, recruited from the Laboratory Medicine Unit of Children's National Health System. Feasibility will be determined based on the percentage of patient participation, as measured by levels of refusal to participate, whether parent or child; ability to inhale the full dose of oil; and ability to inhale the full dose within the ten-minute time frame. This study hopes to learn more about the pain and anxiety experienced during venipuncture in a pediatric population and the use of non- pharmacological approaches to decrease such symptoms.
About Children’s National Health System
Children's National Health System, based in Washington, DC, has been serving the nation's children since 1870. Children's National is a Leapfrog Group Top Hospital, Magnet® designated, and was ranked among the top 10 pediatric hospitals by U.S. News & World Report 2015-16. Home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is one of the nation's top NIH-funded pediatric institutions. With a community-based pediatric network, seven regional outpatient centers, an ambulatory surgery center, two emergency rooms, an acute care hospital, and collaborations throughout the region, Children's National is recognized for its expertise and innovation in pediatric care and as an advocate for all children. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter.
About Aeroscena®
Founded in 2010, Aeroscena®'s mission is to give individuals control over their own well-being via 100% natural, scientifically-backed aromatherapy solutions that are Recommended by doctors, used by hospitals®. Aeroscena® LLC is the privately-held parent company of ascentsTM Clinical Aromatherapy, and is headquartered in Cleveland, OH. For more information, visit http://www.shopascents.com
Mark Kohoot, Aeroscena®, LLC, http://www.shopascents.com, +1 937-551-1890, [email protected]
Share this article